8.0361
price up icon4.76%   0.3661
 
loading
Precedente Chiudi:
$7.67
Aprire:
$7.61
Volume 24 ore:
514.64K
Relative Volume:
0.37
Capitalizzazione di mercato:
$464.75M
Reddito:
$65,400
Utile/perdita netta:
$-46.34M
Rapporto P/E:
-8.7349
EPS:
-0.92
Flusso di cassa netto:
$-38.74M
1 W Prestazione:
+12.69%
1M Prestazione:
-26.35%
6M Prestazione:
-28.26%
1 anno Prestazione:
+52.18%
Intervallo 1D:
Value
$7.5671
$8.10
Intervallo di 1 settimana:
Value
$7.05
$8.10
Portata 52W:
Value
$3.61
$13.85

CorMedix Inc Stock (CRMD) Company Profile

Name
Nome
CorMedix Inc
Name
Telefono
908-517-9500
Name
Indirizzo
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Name
Dipendente
14
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
CRMD's Discussions on Twitter

Confronta CRMD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRMD
CorMedix Inc
8.01 464.75M 65,400 -46.34M -38.74M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
481.65 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.58 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
602.80 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
233.64 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-07 Iniziato Leerink Partners Outperform
2025-01-13 Iniziato D. Boral Capital Buy
2024-08-26 Iniziato Rodman & Renshaw Buy
2023-08-10 Iniziato RBC Capital Mkts Outperform
2021-02-17 Iniziato Needham Buy
2020-09-29 Iniziato JMP Securities Mkt Outperform
2020-09-21 Iniziato Truist Buy
2019-12-18 Iniziato B. Riley FBR Buy
2019-03-26 Reiterato H.C. Wainwright Buy
2018-12-06 Iniziato ROTH Capital Buy
2017-09-25 Reiterato H.C. Wainwright Buy
2017-08-10 Reiterato Rodman & Renshaw Buy
2017-05-05 Reiterato Rodman & Renshaw Buy
2016-11-11 Reiterato FBR & Co. Outperform
2016-03-17 Reiterato FBR Capital Outperform
2016-03-03 Iniziato FBR Capital Outperform
2015-11-16 Reiterato ROTH Capital Neutral
2015-10-29 Reiterato ROTH Capital Neutral
2015-05-06 Downgrade ROTH Capital Buy → Neutral
2014-12-08 Reiterato ROTH Capital Buy
2011-10-03 Downgrade Maxim Group Buy → Hold
Mostra tutto

CorMedix Inc Borsa (CRMD) Ultime notizie

pulisher
Apr 17, 2025

Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years - Yahoo Finance

Apr 17, 2025
pulisher
Apr 09, 2025

RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance

Apr 09, 2025
pulisher
Apr 09, 2025

CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Inc. Raises Financial Guidance for First Half of 2025 - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 29, 2025

CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Mar 28, 2025
pulisher
Mar 27, 2025

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st

Mar 27, 2025
pulisher
Mar 26, 2025

Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

Mar 26, 2025
pulisher
Mar 26, 2025

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com

Mar 26, 2025
pulisher
Mar 26, 2025

Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - Louisiana First News

Mar 26, 2025
pulisher
Mar 26, 2025

Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix: Q4 Earnings Snapshot - MySA

Mar 25, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable

Mar 25, 2025
pulisher
Mar 25, 2025

Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull

Mar 25, 2025
pulisher
Mar 25, 2025

Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix shares tumble after order delay - Investing.com

Mar 25, 2025

CorMedix Inc Azioni (CRMD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.85
price down icon 0.77%
$71.22
price down icon 2.53%
$32.51
price up icon 0.11%
$24.83
price down icon 0.47%
$97.38
price down icon 1.48%
biotechnology ONC
$231.14
price up icon 0.63%
Capitalizzazione:     |  Volume (24 ore):